Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fib
Collaboration combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisationAgreement with Takeda for the discovery and development of novel therapeutics for inflammatory bowel disease (IBD) builds on existing colla...
Source: pharmiweb.com
